TITLE

Insulin-producing neurospheres

PUB. DATE
April 2005
SOURCE
PLoS Medicine;Apr2005, Vol. 2 Issue 4, p269
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Discusses research being done on the differentiation of insulin-producing cells from human neural progenitor cells. Reference to a study by Seung Kim and colleagues published in this issue; Availability of recombinant insulin; Search for renewable sources of insulin-producing cells through human stem cell research.
ACCESSION #
16857924

 

Related Articles

  • Producing Insulin from Neural Cells.  // PLoS Medicine;Apr2005, Vol. 2 Issue 4, p268 

    Discusses research being done on the differentiation of insulin-producing cells from human neural progenitor cells. Reference to a study by Seung Kim and colleagues published in this issue; Availability of recombinant insulin; Search for renewable sources of insulin-producing cells through...

  • Diasome Changes up Insulin Treatments in Diabetes Field. McNeal, Erik // BioWorld Today;7/21/2008, Vol. 19 Issue 140, p2 

    This article talks about the utilization of a bio-based nanotechnological targeting system by Conshohocken, Pennsylvania-based Diasome for the delivery of recombinant human insulin to the hepatocytes of the liver to restore its regular physiological operation, allowing for improved glucose...

  • Construction and characterization of a recombinant human beta defensin 2 fusion protein targeting the epidermal growth factor receptor: in vitro study. Zhang, Minjing; Qiu, Zhuangwei; Li, Yinyu; Yang, Yan; Zhang, Qihao; Xiang, Qi; Su, Zhijian; Huang, Yadong // Applied Microbiology & Biotechnology;May2013, Vol. 97 Issue 9, p3913 

    The HER2/neu proto-oncogene encodes a 185-kDa trans-membrane glycoprotein kinase with extensive homology to the epidermal growth factor receptor and plays a key role in the transformation and growth of malignant tumors. To date, two antibody drugs targeting HER2/neu have been developed...

  • Group action on insulin faces collapse. Dyer, Clare // BMJ: British Medical Journal (International Edition);3/27/93, Vol. 306 Issue 6881, p814 

    Reports the legal action of diabetic patients against the genetically engineered human insulin manufactured by pharmaceutical industry in Great Britain. Harmful effects of the product; Comparison of the biological effects between human and animal insulin; Factors contributing to the...

  • Financings Roundup.  // BioWorld Today;7/16/2008, Vol. 19 Issue 137, p8 

    The article reports on a no-interest loan received by Cytheris SA from OSEO, the national agency for industrial innovation in France, to support its ongoing clinical development program in hepatitis C. The loan is expected to provide partial funding for the hepatitis C virus (HCV) program...

  • THE EFFECTS OF RECOMBINANT HUMAN IGF-1 (INSULIN-LIKE GROWTH FACTOR-1) INJECTION ON LIVER GROWTH IN RATS. Kocamis, H.; Sari, E. Karadag; Aslan, S.; Gulmez, N.; Deprem, T. // Acta Veterinaria;2009, Vol. 59 Issue 1, p25 

    The purpose of the present study was to evaluate the effects of recombinant human (rh) IGF-1 administration on liver growth of rats. RhIGF-1 (100 ng/kg/day prepared in 0.01 M NaHCO3) was injected (s.c) daily to rats for seven days. Control groups received the same injection procedure with only...

  • Insulin: A Voice for Choice. Teuscher, Arthur // Diabetes Health;Dec2007/Jan2008, Vol. 16 Issue 6, p18 

    The article discusses the dangers of hypoglycemic unawareness in diabetics who are taking human insulin. Human insulin came into use in the 1980s as a more physiological alternative to animal insulin, but some patients however reported a sudden loss of symptoms that had previously warned them...

  • insulin aspart.  // Royal Society of Medicine: Medicines;2002, p305 

    The article presents information on insulin aspart, a recombinant biosynthetic human insulin analogue, which is used in diabetic treatment to maintain diabetic patients. Insulin aspart has a faster rate of onset and offset of action than soluble insulin. Administration is by injection.

  • insulin lispro.  // Royal Society of Medicine: Medicines;2002, p305 

    The article presents information on insulin lispro, a recombinant biosynthetic human insulin analogue, which is used in diabetic treatment to maintain diabetic patients. Insulin lispro is relatively short-acting. Administration is by injection.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics